[PDF] Top 20 Depressão, qualidade de vida em idosos institucionalizados
Has 10000 "Depressão, qualidade de vida em idosos institucionalizados" found on our website. Below are the top 20 most common "Depressão, qualidade de vida em idosos institucionalizados".
Parkinson's disease: carbidopa, nausea, and dyskinesia
... nausea, utilizing the same basic chemical mechanism as carbidopa and benserazide: AADC inhibition. Carbidopa and benserazide inhibition is irreversible while 5-HTP inhibi- tion is reversible. The use ... See full document
8
Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
... “severe”. Nausea was the most com- mon with a trend to be more frequent in the CLE group (14% versus ...whereas dyskinesia was more common in the CLE group (7% versus ... See full document
10
Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
... Levodopa/carbidopa/entacapone is a pharmacokinetically optimized levodopa formulation that offers more consistent plasma levodopa levels without deep troughs. Clinical evi- dence in PD patients experiencing motor ... See full document
7
<p>The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review</p>
... ed Parkinson ’ s Disease Rating Scale) in 4 trials, PDQ-39 (39-item Parkinson ’ s Disease Questionnaire) in 2 trials, “ off ” time in 2 trials, on- time with troublesome ... See full document
12
Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson's disease
... Parkinson’s disease (PD) is characterized by a progression of symptoms in the course of time which typically leads to the occurrence of motor complications in the advanced stages of ...stimulation, ... See full document
9
The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel
... of disease man- agement, for example, with therapy decisions, which can become more complex as the disease ...their disease, provide unbiased information and advice as and when appropriate, tailoring ... See full document
29
Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson’s disease
... intrastriatal KN-93 treatment reduced levodopa-induced dyskinesia in PD rats As shown in Figure 3, increased AIMs scores in PD rats were observed in PD rats after administrati[r] ... See full document
7
Effects of blackberry (<em>Morus nigra</em>) fruit juice on levodopa-induced dyskinesia in a mice model of Parkinson's disease
... The first evaluation was carried out on the second day of the study. Average score of AIMS test in all groups was nearly the same indicating that no changes in motor func- tion behaviors happened (control group 0.13 ± ... See full document
8
Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
... The UDysRS total score in the patients receiving aman- tadine improved significantly by 20.7 points at 12 weeks compared with baseline. When compared with placebo, a difference of 14.4 points ( p,0.0001) was found. The ... See full document
5
Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
... We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and three Chinese databases – WanFang Data, Chinese Science and Technology Journal Database, and China National Knowledge Infrastructure – from ... See full document
11
Review: management of Parkinson's disease
... Two methods are available: (1) subcutaneous apomorphine injections “on demand;” or (2) continuous subcutaneous injection by means of a pump. Both forms might cause side effects, the most frequent being nausea and ... See full document
12
Rasagiline in treatment of Parkinson’s disease
... Subjects were randomly assigned to either 1 mg/day rasagiline, 200 mg entacapone with every levodopa dose, or placebo. Levodopa dosage could be reduced in the initial 6 weeks but no change could be made subsequently. The ... See full document
7
Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
... Abbreviations: WBC, white blood cell; rBC, red blood cell; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; rDW, red blood cell distribution width; pLT, platelet; BUN, blood urea nitrogen; asT, aspartate ... See full document
10
Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
... All patients had been taking commercially available IR CD-LD at least four times/day (excluding nighttime dosing), with a levodopa dosage totaling 500–1,600 mg/day, in a regimen that had been stable for at least 1 month. ... See full document
56
Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): [RETIRED]Report of the Quality Standards Subcommittee of the American Academy of Neurology
... and dyskinesia, magnitude of response, adverse events, and levodopa dose ...AND Parkinson disease; DBS AND Par- kinson disease; subthalamic stimulation AND Par- kinson disease; pallidal ... See full document
24
Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
... with carbidopa (CD) and the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) may reduce the onset of these motor complications to a certain ...Parkinson’s disease, preference, compliance, ... See full document
12
Ranitidine reduced levodopa-induced dyskinesia in a rat model of Parkinson’s disease
... with levodopa induced full LID expression in PD rats, includ- ing axial, forelimb, orolingual, and locomotor dyskinesia, as demonstrated by increased AIMS over 22 days. Acute admin- istration of ranitidine had no ... See full document
8
Parkinson’s disease psychosis
... Parkinson’s disease is a progressive neurodegenerative disease characterized by loss of nigral dopaminergic neurons associated with rigidity, resting tremor, bradykinesia, and postural ...Parkinson’s ... See full document
44
Study protocol of “CHAPS”: a randomized controlled trial protocol of Care Coordination for Health Promotion and Activities in Parkinson’s Disease to improve the quality of care for individuals with Parkinson’s disease
... initial Action Plan is orientation to the self-management healthcare notebook and a few priority problems that the Veteran and NCM collaboratively decide are the most important to work on. These Veteran-focused personal- ... See full document
131
<p>Validation study of the Parkinson’s Fatigue Scale in advanced Parkinson’s disease</p>
... ’ s Parkinson ’ s Disease Pain scale; and grant from the International Parkinson and Movement Disorder Society to attend the congress of the society in ... See full document
6
Related subjects